Merck & Co., Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 38/100
What the filing says
Merck reported Q3 2026 sales of $18.085 billion (5% growth), with KEYTRUDA/KEYTRUDA QLEX at $8.601 billion (6% growth) and WINREVAIR at $694 million (93% growth). The company raised full-year 2026 sales guidance to $66.8–$67.3 billion (from $66.3–$67.3B) and non-GAAP EPS guidance to $2.77–$2.82 (from $2.66–$2.76), now including a $0.12/share one-time charge for a global license agreement with SciBrunch. Pipeline highlights include FDA acceptance of sacituzumab tirumotecan (sac-TMT) BLA for endometrial cancer, positive Phase 3 data for intismeran plus KEYTRUDA in melanoma, and FDA approval of WELIREG plus Lenvima for renal cell carcinoma.
Why this rating
Modest revenue beat and guidance raise are routine for a $198B company; strong oncology pipeline adds clinical de-risking but near-term EPS uplift offset by $15.8B in M&A charges ($Cidara $9B, Terns $5.7B).
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.